Adaptive Biotechnologies Corporation (ADPT) vs GRAIL, Inc. (GRAL)
- Adaptive Biotechnologies Corporation ADPT 24.02 −6.10%
- GRAIL, Inc. GRAL 117.81 −13.03%
Adaptive Biotechnologies Corporation and GRAIL, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $6.1B against $4.1B — 1.5× the size. Adaptive Biotechnologies Corporation grew revenue faster over the last twelve months: 50.1% against 23.1%. Adaptive Biotechnologies Corporation has the higher net margin (−20.7% vs −237.0%) and the higher return on invested capital (−16.6% vs −20.8%). Across the 17 metrics below, Adaptive Biotechnologies Corporation leads on 11 and GRAIL, Inc. on 6.
Valuation
Profitability
| Metric | ADPT | GRAL | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 75.57% | (31.31%) | 50.89% |
| Operating margin | (12.16%) | (338.40%) | (8.57%) |
| Net margin | (20.73%) | (236.95%) | (6.37%) |
| Free cash flow margin | (7.80%) | (179.21%) | 0.00% |
| Return on equity | (38.68%) | (16.12%) | (2.92%) |
| Return on assets | (11.23%) | (14.12%) | (6.71%) |
| Return on invested capital | (16.57%) | (20.79%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack